Ebbesen Finn, Rodrigo-Domingo Maria, Moeller Anne M, Vreman Hendrik J, Donneborg Mette L
Department of Pediatrics, Aalborg University Hospital, Aalborg, Denmark.
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Pediatr Res. 2021 Feb;89(3):598-603. doi: 10.1038/s41390-020-0911-9. Epub 2020 Apr 26.
Treatment of choice for hyperbilirubinemic neonates is blue light matching the absorption spectrum of bilirubin-albumin in vitro with maximum absorption at 459 nm. Blue LED light centered at 478 nm was hypothesized as being more efficient than that centered at 459 nm. This study compares the bilirubin-reducing effect of the two light qualities with equal irradiance in a randomized nonblinded clinical trial.
Inclusion criteria were healthy hyperbilirubinemic neonates with gestational age ≥33 weeks. Forty-nine neonates included in each group received phototherapy from above for 24 h. Mean irradiances were 9.2 × 10 and 9.0 × 10 photons/cm/s for the 478 and 459 nm groups, respectively.
Mean [95% CI] decreases in total serum bilirubin were 150 [141, 158] and 120 [111, 130] µmol/L for the 478 and 459 nm groups, respectively; mean difference was 29 [17, 42] µmol/L. Mean [95% CI] percentage decreases in bilirubin were 54.8% [52.5, 57.0] and 41.8% [39.3, 44.3]; mean difference was 12.9 [9.6, 16.3] percentage points. After adjustment this difference was 13.4 [10.2, 16.7] percentage points. All differences were highly statistically significant (P < 0.001).
Blue LED light centered at 478 nm had a greater bilirubin-reducing effect than that centered at 459 nm with equal irradiance quantified as photon fluence rate.
Blue LED light centered at 478 nm had a greater in vivo bilirubin-reducing effect than blue LED light centered at 459 nm with equal irradiance quantified as photon fluence rate in the treatment of hyperbilirubinemic late preterm or term neonates. LED light centered at 478 nm might reduce the duration of phototherapy compared to LED light centered at 459 nm as the same effect can be obtained while exposing the infants to fewer photons. Blue light matching the absorption spectrum of the bilirubin-albumin complex in vitro with peak absorption at 459 nm is used worldwide as it is considered to be the most effective light for phototherapy of jaundiced neonates. This study showed that blue LED light centered at 478 nm had a greater bilirubin-reducing effect than blue LED light centered at 459 nm. Therefore, blue LED light centered at 478 nm should be used instead of blue light centered at 459 nm. By this, the risk of potential side effects might be minimized, and the duration of phototherapy potentially reduced.
高胆红素血症新生儿的首选治疗方法是蓝光,其在体外与胆红素 - 白蛋白的吸收光谱相匹配,在459nm处有最大吸收。据推测,以478nm为中心的蓝色发光二极管(LED)光比以459nm为中心的光更有效。本研究在一项随机非盲临床试验中比较了两种具有相同辐照度的光质降低胆红素的效果。
纳入标准为孕周≥33周的健康高胆红素血症新生儿。每组49名新生儿接受上方光疗24小时。478nm组和459nm组的平均辐照度分别为9.2×10和9.0×10光子/厘米²/秒。
478nm组和459nm组总血清胆红素的平均[95%置信区间]下降分别为150[141,158]和120[111,130]μmol/L;平均差异为29[17,42]μmol/L。胆红素的平均[95%置信区间]下降百分比分别为54.8%[52.5,57.0]和41.8%[39.3,44.3];平均差异为12.9[9.6,16.3]个百分点。调整后该差异为13.4[10.2,16.7]个百分点。所有差异均具有高度统计学意义(P<0.001)。
在相同辐照度(以光子通量率量化)下,以478nm为中心的蓝色LED光比以459nm为中心的光具有更强的降低胆红素效果。
在治疗晚期早产儿或足月儿高胆红素血症时,在相同辐照度(以光子通量率量化)下,以478nm为中心的蓝色LED光比以459nm为中心的蓝色LED光在体内具有更强的降低胆红素效果。与以459nm为中心的LED光相比,以478nm为中心的LED光可能会缩短光疗时间,因为在使婴儿暴露于较少光子的情况下可获得相同效果。在体外与胆红素 - 白蛋白复合物吸收光谱相匹配且在459nm处有峰值吸收的蓝光在全球范围内被用作治疗黄疸新生儿的最有效光。本研究表明,以478nm为中心的蓝色LED光比以459nm为中心的蓝色LED光具有更强的降低胆红素效果。因此,应使用以478nm为中心的蓝色LED光代替以459nm为中心的蓝光。通过这样做,潜在副作用的风险可能会降至最低,光疗时间也可能会缩短。